A.P. Pharma submits anti-nausea drug for FDA approval

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 6
Volume 18
Issue 6

APF530 is undergoing regulatory review for a new drug approval for the prevention of chemotherapy-induced nausea and vomiting, according to manufacturer A.P. Pharma. PF530 is a formulation of granisetron, a 5-HT3 antagonist.

APF530 is undergoing regulatory review for a new drug approval for the prevention of chemotherapy-induced nausea and vomiting, according to manufacturer A.P. Pharma. PF530 is a formulation of granisetron, a 5-HT3 antagonist.

The drug is delivered using the company’s Biochronomer system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection.

In a phase III, randomized, multicenter trial of 1,395 cancer patients, APF530 was shown to be as effective as palonosetron (Aloxi) for the prevention of acute onset and delayed onset CINV, A.P. Pharma said in a statement.

Recent Videos
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
Experts from Vanderbilt University Medical Center emphasize gathering a second opinion to determine if a tumor is resectable in patients with pancreatic cancer.
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Experts from Vanderbilt University Medical Center discuss the use of intraoperative radiation therapy in a 64-year-old patient with pancreatic cancer.
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Related Content